Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2055-2058

  Advani, Sunil J ^a   Chung, Su Mi ^a   Yan, Sze Y ^a   Gillespie, G Yancey ^b   Markert, James M ^b   Whitley, Richard J ^c   Roizman, Bernard ^d   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SQUAMOUS CELL CARCINOMA; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, VIRAL; GENES, P53; GENETIC ENGINEERING; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; SIMPLEXVIRUS; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

EID: 0033135055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 25: 1550-1552, 1992.
2. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 27: 373-376, 1996.
3. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
4. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
5. Goodrum, F. D., and Ornelles, D. A. p53 status does not determine outcome of EIb 55 kilodalton mutant adenovirus lytic infection. J. Virol., 72: 9479-9490, 1998.
6. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
7. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991.
8. Mineta, T., Rabkin, S. D., and Martuza, R. L. Treatment of malignant gliomas using gancyclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54: 3963-3966, 1994.
9. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. Mapping of herpes simplex virus-1 neurovirulence to γI34.5, a gene nonessential for growth in culture. Science (Washington DC), 250; 1262-1266, 1990.
10. Andreansky, S., Soroceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B., and Whitley, R. J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res., 57: 1502-1509, 1997.
11. Advani, S. J., Sibley, G. S., Song, P. Y., Hallahan, D. E., Kataoka, Y., Roizman, B., and Weichselbaum, R. R. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther, 5: 160-165, 1998.
12. Meignier, B., Longnecker, R., and Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis., 158: 602-614, 1988.
13. Roizman, B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc. Natl. Acad. Sci. USA, 93: 11307-11312, 1996.
14. Meignier, B., Martin, B., Whitley, R. J., and Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162: 313-321, 1990.
15. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne, J. D., Hanna, N. N., Toledano, A., Hellman, S., Kufe, D. W., and Weichselbaum, R. R. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med., 1: 786-791, 1995.
16. Ghosh, J., and Myers, C. E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA, 95: 13182-13187, 1998.
17. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
18. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
19. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ., 6: 363-370, 1995.
20. Koivisto, P., Kolmer, M., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol., 152: 1-9, 1998.
21. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
22. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
23. Tang, D. C., Jennelle, R. S., Shi, Z., Garver, R. I., Jr., Carbone, D. P., Loya, F., Chang, C. H., and Curiel, D. T. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum. Gene Ther., 8: 2117-2124, 1997.
24. Weichselbaum, R. R., Hallahan, D. E., Sukhatme, V., Dritschilo, A., Sherman, M. L., and Kufe, D. W. Biological consequences of gene regulation after ionizing radiation exposure. J. Natl. Cancer Inst., 83: 480-484, 1991.